Physician profile
Christopher Corrales
NPI 1336630656
$820.47
in general payments reported to CMS, 2019-2025
15 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.55 · 2022: $97.67 · 2023: $72.21 · 2024: $443 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $664 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $664.45 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $259.36 | 2021-2025 | Ubrelvy |
| Lilly USA, LLC | $131.18 | 2022-2025 | Zepbound, Jardiance |
| Pfizer INC. | $65.81 | 2024-2025 | |
| Novo Nordisk INC | $55.24 | 2024-2025 | Ozempic, Rybelsus, Saxenda |
| Gilead Sciences, INC. | $54.39 | 2023-2024 | |
| Viiv Healthcare Company | $48.12 | 2024-2025 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $44.73 | 2024 | |
| Inspire Medical Systems, INC. | $30.79 | 2024 | Inspire |
| Edwards Lifesciences Corporation | $25.27 | 2022 | |
| Abbott Laboratories | $22.41 | 2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $21.43 | 2025 | Rexulti |
| Tris Pharma INC | $16.43 | 2024 | Dyanavel Xr |
| Exact Sciences Corporation | $16.24 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.91 | 2022 | |
| Merck Sharp & Dohme LLC | $14.16 | 2023 | Vaqta, Vaxneuvance, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Corrales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.